Benzinga | Sep 10, 2020 07:04AM EDT

Biohaven's Oral Zavegepan Receives Authorization To Proceed From FDA And Achieves First In Human Dosing

NEW HAVEN, Conn., Sept. 10, 2020 /PRNewswire/ --Biohaven Pharmaceutical Holding Company Ltd. (NYSE:BHVN), a commercial-stage biopharmaceutical company with a portfolio of innovative, late-stage product candidates targeting neurological and neuropsychiatric diseases, today reported that the U.S. Food and Drug Administration (FDA) has authorized the initiation of clinical trials for oral zavegepant (formerly BHV-3500) and that the company has achieved first in human dosing in a Phase 1 trial designed to assess the safety and pharmacokinetics of oral formulations of zavegepant.